Retatrutide is not FDA-approved and cannot legally be compounded. Here is why online sales are booming, what buyers may receive, and why Lilly is suing.

GLP-1 drugs are no longer staying inside the doctor’s office. In July, they showed up in dating research, household insurance bills, and a federal courtroom.

Medicare is about to let some people get GLP-1 weight-loss drugs for $50 a month. That sounds simple. This is American healthcare, so naturally, there is a bridge, a toll booth, several eligibility signs, and a pharmacist trying to find the right billing code. For the past few years, the GLP-1 weight-loss drugs story has mostly sounded like this: A patient hears about Wegovy or Zepbound. A doctor agrees it may help. The patient walks to the pharmacy. The pharmacy says somethi

GLP-1 drugs were first sold to the public as weight-loss medicine. But the bigger story may be happening in the brain. Patients are not just reporting smaller portions or slower digestion. Many describe a quieter relationship with food itself, as if the constant background noise of craving has finally lowered its volume. That can be a gift. It can also be a warning. When a medicine changes appetite, cravings, and possibly reward signals, the conversation has to move beyond p

The complexities of expired Ozempic patent and medical tourism

As AI races ahead, America’s obesity crisis is still grounded in costly reality. This March 2026 PoundsPunch feature examines how GLP-1 drugs, new policy experiments, supply-chain strain, and global generic competition are reshaping the future of weight loss treatment.

Weight-loss drug prices are no longer a simple four-digit shock. As of February 27, 2026, what you pay for Wegovy, Ozempic, Zepbound, or Mounjaro depends entirely on how you buy it — insurance, self-pay, or the new TrumpRx platform. Monthly costs now range from as low as $25 for some commercially insured patients to $1,000 or more for others paying retail. With confirmed list-price cuts ahead and a full-blown price war underway, the obesity drug market has entered a new era.

Why does the weight come back so fast after stopping GLP-1 drugs?

In 2025, other countries negotiated, rationed, and planned for weight-loss drugs. The U.S. finally moved—but still missed the bigger lesson.

Wegovy can cost over $1,300 a month—but 340B quietly reshapes who pockets that money. We follow the dollars from patient to hospital, pharmacy, PBM, and Novo Nordisk.

Hospitals and clinics get big price breaks on brand-name drugs under the 340B program. Here’s how it works, who benefits, and who doesn’t.

Who really sets the price of weight-loss drugs? Wegovy and Zepbound cost over $1,000 a month—unless you know the right channel. Pharma, PBMs, and employers all play the game, while patients and pharmacies are left paying up. Our special report unpacks the hidden power struggle behind the “$499 deal.”

Lilly’s once‑daily pill posts late‑stage successes. Here’s what the data really say, how it stacks up against rivals, and what to expect on price, coverage, and patient experience.

Novo Nordisk faced critical leadership changes and mounting challenges from Pharmacy Benefit Managers (PBMs) amid fierce competition in the obesity drug market. With a new CEO recently appointed, the company is also doubling down on strategic partnerships in China, aiming to innovate its research pipeline. However, questions remain about the global acceptance of clinical data from these collaborations and the sustainability of Novo’s market position.

The “Research Use Only” Peptide Market Isn’t Slowing Down—It’s Evolving